BMY - Bristol-Myers Squibb Co Stock Price, Fair Value and News

$49.79+0.85 (+1.74%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BMY Price Action

Last 7 days

-0.4%

Last 30 days

-18.5%

Last 90 days

-12.8%

Trailing 12 Months

1.3%

BMY RSI Chart

BMY Valuation

Market Cap

101.0B

Price/Earnings (Trailing)

-11.29

Price/Sales (Trailing)

2.09

EV/EBITDA

113.26

Price/Free Cashflow

7.25

BMY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BMY Fundamentals

BMY Revenue

Revenue (TTM)

48.3B

Rev. Growth (Yr)

7.54%

Rev. Growth (Qtr)

3.78%

BMY Earnings

Earnings (TTM)

-8.9B

Earnings Growth (Yr)

-98.17%

Earnings Growth (Qtr)

-94.05%

BMY Profitability

EBT Margin

-17.35%

Return on Equity

-54.78%

Return on Assets

-9.66%

Free Cashflow Yield

13.8%

BMY Investor Care

Dividend Yield

4.86%

Dividend/Share (TTM)

2.42

Shares Dilution (1Y)

0.35%

Diluted EPS (TTM)

-4.41

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	45.5B	46.5B	47.4B	48.3B
2023	45.8B	45.2B	44.9B	45.0B
2022	47.0B	47.1B	46.7B	46.2B
2021	42.8B	44.4B	45.5B	46.4B
2020	31.0B	34.9B	39.4B	42.5B
2019	23.3B	23.9B	24.2B	26.1B
2018	21.0B	21.6B	22.0B	22.6B
2017	20.0B	20.2B	20.6B	20.8B
2016	16.9B	17.6B	18.5B	19.4B
2015	16.1B	16.4B	16.5B	16.6B
2014	16.4B	16.2B	16.1B	15.9B
2013	16.2B	15.8B	16.1B	16.4B
2012	21.5B	20.5B	18.9B	17.6B
2011	19.7B	20.4B	20.9B	21.2B
2010	19.3B	19.4B	19.4B	19.5B

Get all data in R, Python etc through our Historical Stock Data APIs

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

CEO	Dr. Giovanni Caforio M.D.
WEBSITE	bms.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers General
EMPLOYEES	34300

Bristol-Myers Squibb Co Frequently Asked Questions

What is the ticker symbol for Bristol-Myers Squibb Co? What does BMY stand for in stocks?

BMY is the stock ticker symbol of Bristol-Myers Squibb Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bristol-Myers Squibb Co (BMY)?

As of Tue Apr 22 2025, market cap of Bristol-Myers Squibb Co is 101.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMY stock?

You can check BMY's fair value in chart for subscribers.

Is Bristol-Myers Squibb Co a good stock to buy?

The fair value guage provides a quick view whether BMY is over valued or under valued. Whether Bristol-Myers Squibb Co is cheap or expensive depends on the assumptions which impact Bristol-Myers Squibb Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMY.

What is Bristol-Myers Squibb Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 22 2025, BMY's PE ratio (Price to Earnings) is -11.29 and Price to Sales (PS) ratio is 2.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bristol-Myers Squibb Co's stock?

In the past 10 years, Bristol-Myers Squibb Co has provided -0.028 (multiply by 100 for percentage) rate of return.